AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma?
On 30 May, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, AstraZeneca will release the…
Oncology
-
-
Consecutive approvals of Opdivo for Hodgkin’s lymphoma to boost sales growth
On 20 March, Bristol Myers Squibb (BMS) announced that the FDA granted approval for Opdivo (nivolumab), an immune checkpoint inhibitor…
-
ASH 2025: Eli Lilly’s Jaypirca emerges as a strong first-line contender in CLL/SLL
At the American Society of Hematology (ASH) Annual Meeting, held on 6-9 December updated results from the global, multi-centre, open-label,…
-
ESMO 2025: potential new adjuvant option ensartinib for ALK+ NSCLC
At the 2025 European Society of Medical Oncology (ESMO) Congress, held on 17 to 21 October in Berlin, Germany, results…
-
Asbestos-related cancers still prevalent in the UK
Asbestos is a naturally occurring mineral that is resistant to heat and corrosion. These properties make it suitable for insulation…
-
GSK’s anti-TIM-3 antibody fails in Phase III NSCLC trial
GSK’s anti-TIM monoclonal antibody (mAb) cobolimab has failed a Phase III trial in non-small cell lung cancer (NSCLC). The COSTAR Lung…
-
EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma
At the 2025 European Hematology Association (EHA) Congress, held from June 12 to June 15 in Milan, Italy, updated results…
-
Implementing pragmatic approaches for the patients and sites in oncology trials
Is the clinical trials field doing enough to centre the needs and concerns of patients in research? That was the…
-
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
AbbVie’s antibody drug conjugate (ADC) Temab-A (telisotuzumab adizutecan) has demonstrated promising results in a Phase I trial in patients with…
-
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
Roche’s blockbuster vision for phosphoinositide 3-kinase (PI3K inhibitor) Itovebi (inavolisib) has been dealt a boost after the drug demonstrated further…
